Patient Information on Clinical Trials

Participate in a Clinical Trial 

Thanks for your involvement!

Clinical trials are a key research tool for advancing medical knowledge and patient care. The knowledge gained will support the treatment we will provide in the years to come. Clinical trials can provide positive impacts for many patients in the future, offering benefits such as new treatments or better drug options. Through rigorous testing, evidence-based trials ensure the solutions are safe and effective before they are used in clinical practice.

 

Benefits of Clinical Trials  

  • You may receive a new treatment for a disease or condition before it is publicly available.
  • You play a more active role in your own health care.
  • Researchers may provide you with medical care and more frequent health check-ups as part of your treatment.
  • You may have the chance to help others get better treatment for their health problems in the future.
  • You may be able to get information about support groups and resources.
If you would like to participate in any of our future research studies or would like any information on our current projects, please contact our research department at research@wdmh.on.ca.

 

research team 

Current Clinical Trials 


Asthma VALIANT - Upstream Bio 

 

Valiant Ashtma ad 

 

Atherosclerosis POSEIDON - NovoNordisk

The role of inflammation in atherosclerosis has been well established, and atherosclerosis is currently considered a hybrid disease between a metabolic disorder and chronic systemic inflammation. There is also evidence showing a link between systemic inflammation and risk of cardiovascular complications. C-reactive protein (CRP) has been shown to be a reliable measure of underlying systemic inflammation and a strong predictor of future cardiovascular events.  

 

This study will use a cross-sectional approach and conduct testing in a large sample of patients to better understand the prevalence of systemic inflammation in patients with atherosclerotic cardiovascular disease or heart failure.  



Heart Failure HERMES - NovoNordisk

The current study is to demonstrate the efficacy of ziltivekimab in reducing morbidity and mortality in patients with heart failure (HF) with mildly reduced ejection fraction (HFmrEF) or HF with preserved ejection fraction (HFpEF) and systemic inflammation.


Primary inclusion criteria: Adults aged 18+ with a clinical diagnosis of heart failure (NYHA Class II-IV), and LVEF > 40%.


COPD MIRANDA - Astra Zeneca

Info to come  

 

Asthma FLAIR - Teva

Info to come 

 

Obesity TRIUMPH - Eli Lilly  

Info to come 

 


If you would like to participate in any of our future research studies or would like any information on our current projects, please contact our research department at research@wdmh.on.ca.